Dashboard
Manage Tickers

SRPT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

expert-outlook-sarepta-therapeutics-through-the-eyes-of-25-analysts
Expert Outlook: Sarepta Therapeutics Throu...
07/01/2024 14:01:19

piper-sandler-maintains-overweight-on-sarepta-therapeutics-maintains-205-price-target
Piper Sandler Maintains Overweight on Sare...
07/01/2024 13:53:42

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and maintains $205 price tar...

needham-reiterates-buy-on-sarepta-therapeutics-maintains-235-price-target
Needham Reiterates Buy on Sarepta Therapeu...
06/27/2024 10:06:55

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $235 price target.

looking-at-sarepta-therapeuticss-recent-unusual-options-activity
Looking At Sarepta Therapeutics's Recent U...
06/26/2024 15:16:27

citigroup-downgrades-sarepta-therapeutics-to-neutral-raises-price-target-to-176
Citigroup Downgrades Sarepta Therapeutics ...
06/26/2024 14:27:52

Citigroup analyst David Hoang downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Buy to Neutral and raises the price target ...

heres-how-much-you-would-have-made-owning-sarepta-therapeutics-stock-in-the-last-10-years
Here's How Much You Would Have Made Owning...
06/24/2024 20:00:30

morgan-stanley-maintains-overweight-on-sarepta-therapeutics-raises-price-target-to-200
Morgan Stanley Maintains Overweight on Sar...
06/24/2024 16:18:07

Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price ...

evercore-isi-group-maintains-in-line-on-sarepta-therapeutics-raises-price-target-to-185
Evercore ISI Group Maintains In-Line on Sa...
06/24/2024 14:12:39

Evercore ISI Group analyst Gavin Clark-Gartner maintains Sarepta Therapeutics (NASDAQ:SRPT) with a In-Line and raises the pr...

micron-to-rally-around-23-here-are-10-top-analyst-forecasts-for-monday
Micron To Rally Around 23%? Here Are 10 To...
06/24/2024 12:25:05

bmo-capital-maintains-outperform-on-sarepta-therapeutics-raises-price-target-to-200
BMO Capital Maintains Outperform on Sarept...
06/24/2024 11:54:31

BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price tar...

leerink-partners-maintains-outperform-on-sarepta-therapeutics-raises-price-target-to-230
Leerink Partners Maintains Outperform on S...
06/24/2024 11:19:37

Leerink Partners analyst Mani Foroohar maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price t...

draftkings-and-dell-were-among-the-10-biggest-large-cap-stock-gainers-last-week-june-16-june-22-are-these-in-your-portfolio
DraftKings And Dell Were Among The 10 Bigg...
06/23/2024 15:43:40

Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKN...

growth-stocks-leave-value-stocks-in-the-dust-4-reasons-for-biggest-monthly-lead-in-over-a-year
Growth Stocks Leave Value Stocks In The Du...
06/21/2024 20:06:46

Technology sector dominates growth stocks, boosted by strong earnings and investor confidence. Value stocks struggle due to les...

nasdaq-moves-lower-factset-research-posts-upbeat-earnings
Nasdaq Moves Lower; FactSet Research Posts...
06/21/2024 18:58:10

why-kaival-brands-innovations-shares-are-trading-lower-by-47-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Kaival Brands Innovations Shares Are T...
06/21/2024 18:04:00

morgan-stanley-reiterates-overweight-on-sarepta-therapeutics-maintains-165-price-target
Morgan Stanley Reiterates Overweight on Sa...
06/21/2024 17:56:25

Morgan Stanley analyst Matthew Harrison reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and maintains $165 p...

sareptas-expanded-approval-unlikely-to-influence-novo-holdings-acquisition-of-catalent-but-provides-investor-protection-amid-uncertainty
Sarepta's Expanded Approval Unlikely To In...
06/21/2024 17:52:17

Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/rew...

stocks-stall-as-chip-sector-struggles-to-rebound-dollar-eyes-7-week-peak-gold-bitcoin-retreat-whats-driving-markets-friday
Stocks Stall As Chip Sector Struggles To R...
06/21/2024 17:34:44

Wall Street is experiencing a subdued and low volatility trading day Friday, despite the session coinciding with the “triple wi...

piper-sandler-maintains-overweight-on-sarepta-therapeutics-maintains-157-price-target
Piper Sandler Maintains Overweight on Sare...
06/21/2024 17:06:36

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and maintains $157 price tar...

sareptas-expanded-fda-approval-for-elevidys-potentially-shaping-future-fda-reviews-analyst-says
Sarepta's Expanded FDA Approval For Elevid...
06/21/2024 16:50:38

FDA approves Sarepta's Elevidys for Duchenne muscular dystrophy patients with confirmed DMD gene mutation, aged 4+. Expande...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)